Anhco Nguyen Sells 3,331 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Anhco Nguyen sold 3,331 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $7.00, for a total value of $23,317.00. Following the completion of the sale, the chief executive officer now directly owns 74,123 shares of the company’s stock, valued at approximately $518,861. This trade represents a 4.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Atara Biotherapeutics Stock Up 2.5 %

NASDAQ ATRA opened at $7.31 on Thursday. Atara Biotherapeutics, Inc. has a fifty-two week low of $5.40 and a fifty-two week high of $20.81. The stock has a market cap of $42.11 million, a price-to-earnings ratio of -0.28 and a beta of 0.46. The business has a fifty day moving average of $10.09 and a 200-day moving average of $9.75.

Hedge Funds Weigh In On Atara Biotherapeutics

Institutional investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in Atara Biotherapeutics in the fourth quarter valued at $48,000. Northern Trust Corp purchased a new stake in Atara Biotherapeutics during the fourth quarter valued at about $149,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Atara Biotherapeutics in the fourth quarter worth about $169,000. State Street Corp boosted its position in shares of Atara Biotherapeutics by 52.3% in the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after buying an additional 7,680 shares during the period. Finally, FMR LLC boosted its position in shares of Atara Biotherapeutics by 41.7% in the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after buying an additional 7,381 shares during the period. 70.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ATRA has been the subject of a number of research analyst reports. Rodman & Renshaw initiated coverage on Atara Biotherapeutics in a research report on Friday, December 20th. They issued a “buy” rating and a $25.00 target price for the company. RODMAN&RENSHAW cut Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 21st. Canaccord Genuity Group lowered their target price on Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, January 17th. TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a report on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.75.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.